Generated October 19, 2026 at 1:37 PM ET
· Covers October 19 trading day
· 10 of 70 ready 8-Ks selected
· AI-assisted overview
Expand Energy named Daniel E. Brown President and CEO effective October 26, 2026, succeeding interim CEO Michael Wichterich. EyePoint reported that DURAVYU missed the primary endpoint in the Phase 3 LUCIA trial in wet AMD, said it would conclude both pivotal wet AMD trials early, and outlined an approximately 53% workforce reduction; two selected cards covered the same event. Disc Medicine reported that bitopertin met all Phase 3 APOLLO endpoints in EPP and planned an NDA resubmission for end-2026, while Clene submitted an FDA NDA for CNM-Au8 in ALS seeking accelerated approval and BioCardia said FDA accepted its revised De Novo pre-submission for the Helix catheter. Super League holders approved Metaplanet’s Bitcoin investment and a rename to Superplanet with ticker SUPA, and MKS agreed to sell Ophir Optics to TTM Technologies for $650 million in cash, expected to close in Q2 2027. Ultragenyx settled DOJOLVI patent litigation with Navinta, with generic entry set for January 1, 2033.
leadership
positive
materiality 0.75
October 19, 2026, 8:09 AM ET
Expand Energy names Daniel E. Brown President and CEO effective October 26, 2026
- Brown, 51, was CEO of Chord Energy (CHRD) from July 2024 to October 2026 and succeeds interim CEO Michael Wichterich at Expand Energy (EXE).
- Brown's base salary is $1,000,000 with a 125% target bonus and $8,750,000 annual long-term incentive target split 30% RSUs and 70% PSUs.
- Make-whole award comprises $4,726,662 in RSUs and $10,925,584 in PSUs to replace compensation forfeited at his prior employer.
other material
negative
materiality 0.90
October 19, 2026, 9:22 AM ET
EyePoint's DURAVYU misses Phase 3 LUCIA primary endpoint; 53% workforce cut, wet AMD trials halted
- Phase 3 LUCIA study of DURAVYU in wet AMD did not meet the primary endpoint of non-inferiority, though vision improved and key secondary endpoints were met.
- EyePoint will conclude both pivotal Phase 3 wet AMD trials early, without completing year two, and cut approximately 53% of positions, mostly in Q4 2026, finishing in 1H 2027.
- Restructuring carries about $9M in severance and related charges but is expected to generate roughly $30M in annualized savings.
SLE
Super League Enterprise, Inc.
M&A
positive
materiality 0.85
October 19, 2026, 8:00 AM ET
Super League holders approve Metaplanet's 2,100 BTC ($170M) investment; renamed Superplanet, ticker SUPA
- Stockholders approved all 2026 Annual Meeting proposals, including issuance of up to 435,859,500 shares under the Aug 18, 2026 subscription agreements with Metaplanet Holdings and Evo Fund.
- Metaplanet contributes 2,100 Bitcoin plus $2.5M cash — ~$132.1M at the Aug 14 reference date, ~$170.0M as of Oct 16; company separately bought 2 Bitcoin Oct 16 at $81,444.82 avg.
- Metaplanet receives 44,859,400 shares at $3.00, 100 convertible perpetual preferred shares and 10-year warrants for up to 381,000,000 shares at $3.00-$33.50.
M&A
positive
materiality 0.80
October 19, 2026, 8:17 AM ET
MKS to sell Ophir Optics to TTM for $650M in cash; deal expected to close Q2 2027
- Definitive agreement: MKS will sell its Ophir Optics business to TTM Technologies for $650M all cash, subject to customary closing adjustments.
- Price is over 18x projected FY 2026 Adjusted EBITDA for Ophir Optics; expected close in Q2 2027 pending regulatory approvals and governmental consents/permits.
- Ophir Optics supplies high-precision infrared thermal imaging and laser optics for defense, security and industrial customers in MKS’ Specialty Industrial market.
regulatory
positive
materiality 0.80
October 19, 2026, 8:05 AM ET
Clene submits FDA NDA for ALS drug CNM-Au8, seeking accelerated approval
- NDA submitted to FDA earlier in October 2026 for CNM-Au8 in ALS; Clene publicly announced the submission on October 19, 2026.
- Application seeks accelerated approval based on neurofilament light chain biomarker data plus clinical outcomes.
- CEO Rob Etherington cited the FDA's "constructive engagement" and said Clene will work closely with the agency during review.
TTMI
TTM TECHNOLOGIES INC
M&A
positive
materiality 0.78
October 19, 2026, 8:16 AM ET
TTM to buy MKS's Ophir Optics for $650M cash at ~10.3x FY27 EBITDA, accretive to EPS
- All-cash $650M deal for Ophir Optics, an Israel- and Romania-based maker of high-precision infrared thermal imaging and laser optics for defense, security and industrial uses.
- Purchase multiple ~10.3x Ophir's expected FY2027 Adjusted EBITDA without synergies; TTM expects immediate accretion to Adjusted EBITDA margin and non-GAAP diluted EPS.
- Expected to close in Q2 2027, subject to customary closing conditions including certain regulatory approvals and governmental consents and permits.
regulatory
positive
materiality 0.55
October 19, 2026, 9:15 AM ET
BioCardia says FDA accepted Helix catheter De Novo pre-submission; review meeting expected this quarter
- FDA accepted BioCardia's revised De Novo pre-submission package for marketing clearance of the Helix transendocardial delivery catheter, per the Oct. 19, 2026 release.
- In May 2026 FDA agreed two pathways exist for Helix clearance and raised no concerns on the product's safety data, performance, or compatibility with general classes of agents.
- FDA confirmed the meeting minutes in August 2026; BioCardia revised and resubmitted the package in September 2026 incorporating CDRH advice.
other material
positive
materiality 0.92
October 19, 2026, 7:08 AM ET
Disc Medicine's bitopertin meets all Phase 3 APOLLO endpoints in EPP; NDA resubmission planned for end-2026
- Phase 3 APOLLO enrolled 183 EPP/XLP patients aged 12+ across US, Canada, Europe, Australia; randomized 1:1 to 60 mg oral bitopertin or placebo for 6 months.
- Co-primary endpoints met: whole-blood metal-free PPIX fell 41.4% vs placebo (p<0.0001); average monthly pain-free light time rose 12.2 hours in month 6 (p=0.0010).
- All secondary endpoints significant: lower phototoxic reaction incidence (p<0.0001), more cumulative pain-free light time (p<0.0001), improved PGIC and PGIS scores (p<0.0001).
other material
negative
materiality 0.87
October 19, 2026, 7:05 AM ET
EyePoint's LUCIA Phase 3 DURAVYU trial misses primary BCVA non-inferiority endpoint in wet AMD
- LUCIA (475 patients) failed the primary endpoint of statistical non-inferiority in mean BCVA change vs on-label 2 mg aflibercept, despite demonstrating visual improvement.
- Key secondary endpoints met: 38% reduction in treatment burden (nominal p<0.0001), 52% of eyes supplement-free and 71% receiving zero or one supplement through Week 56.
- Favorable safety profile with redosing and strong anatomic control at Week 56, consistent with LUGANO (432 patients), which also missed its primary endpoint.
RARE
Ultragenyx Pharmaceutical Inc.
litigation
positive
materiality 0.45
October 19, 2026, 9:00 AM ET
Ultragenyx settles DOJOLVI patent suit with Navinta; generic entry set for Jan 1, 2033
- Settlement among Ultragenyx, Baylor Research Institute and Navinta LLC resolves ANDA patent litigation in the U.S. District Court for the District of New Jersey over DOJOLVI (triheptanoin).
- Navinta receives a non-exclusive, royalty-free license to market its generic DOJOLVI beginning January 1, 2033, extending to July 1, 2033 if pediatric exclusivity is granted.
- Litigation against other ANDA filers seeking generic DOJOLVI approval remains pending in the U.S. District Court for the District of New Jersey.